155 related articles for article (PubMed ID: 27150538)
1. Blockade of RAS-Binding Domain Interactions Inhibits RAS Signaling.
Cancer Discov; 2016 Jun; 6(6):573. PubMed ID: 27150538
[TBL] [Abstract][Full Text] [Related]
2. A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.
Athuluri-Divakar SK; Vasquez-Del Carpio R; Dutta K; Baker SJ; Cosenza SC; Basu I; Gupta YK; Reddy MV; Ueno L; Hart JR; Vogt PK; Mulholland D; Guha C; Aggarwal AK; Reddy EP
Cell; 2016 Apr; 165(3):643-55. PubMed ID: 27104980
[TBL] [Abstract][Full Text] [Related]
3. A Contaminant Impurity, Not Rigosertib, Is a Tubulin Binding Agent.
Baker SJ; Cosenza SC; Athuluri-Divakar S; Reddy MVR; Vasquez-Del Carpio R; Jain R; Aggarwal AK; Reddy EP
Mol Cell; 2020 Jul; 79(1):180-190.e4. PubMed ID: 32619468
[TBL] [Abstract][Full Text] [Related]
4. Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade.
Yan C; Saleh N; Yang J; Nebhan CA; Vilgelm AE; Reddy EP; Roland JT; Johnson DB; Chen SC; Shattuck-Brandt RL; Ayers GD; Richmond A
Mol Cancer; 2021 Jun; 20(1):85. PubMed ID: 34092233
[TBL] [Abstract][Full Text] [Related]
5. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.
Xu F; He Q; Li X; Chang CK; Wu LY; Zhang Z; Liu L; Shi WH; Zhu Y; Zhao YS; Gu SC; Fei CM; Guo J; Wu D; Zhou L
Sci Rep; 2014 Dec; 4():7310. PubMed ID: 25472472
[TBL] [Abstract][Full Text] [Related]
6. The RAS-Effector Interaction as a Drug Target.
Keeton AB; Salter EA; Piazza GA
Cancer Res; 2017 Jan; 77(2):221-226. PubMed ID: 28062402
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive analysis of RAS-effector interactions reveals interaction hotspots and new binding partners.
Rezaei Adariani S; Kazemein Jasemi NS; Bazgir F; Wittich C; Amin E; Seidel CAM; Dvorsky R; Ahmadian MR
J Biol Chem; 2021; 296():100626. PubMed ID: 33930461
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer.
Chuang HC; Huang PH; Kulp SK; Chen CS
Pharmacol Res; 2017 Mar; 117():370-376. PubMed ID: 28077300
[TBL] [Abstract][Full Text] [Related]
9. Blocking Ras inhibition as an antitumor strategy.
Marín-Ramos NI; Ortega-Gutiérrez S; López-Rodríguez ML
Semin Cancer Biol; 2019 Feb; 54():91-100. PubMed ID: 29409706
[TBL] [Abstract][Full Text] [Related]
10. Bioblockades join the assault on small G protein signalling.
Mott HR; Owen D
Semin Cancer Biol; 2019 Feb; 54():149-161. PubMed ID: 29307570
[TBL] [Abstract][Full Text] [Related]
11. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
Patricelli MP; Janes MR; Li LS; Hansen R; Peters U; Kessler LV; Chen Y; Kucharski JM; Feng J; Ely T; Chen JH; Firdaus SJ; Babbar A; Ren P; Liu Y
Cancer Discov; 2016 Mar; 6(3):316-29. PubMed ID: 26739882
[TBL] [Abstract][Full Text] [Related]
12. Direct Inhibitors of Ras-Effector Protein Interactions.
Upadhyaya P; Bedewy W; Pei D
Mini Rev Med Chem; 2016; 16(5):376-82. PubMed ID: 26423701
[TBL] [Abstract][Full Text] [Related]
13. [Targeting Ras related proteins for leukemia therapy].
Kimura S; Maekawa T
Rinsho Ketsueki; 2005 Mar; 46(3):179-86. PubMed ID: 16447712
[No Abstract] [Full Text] [Related]
14. Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.
Herrero A; Pinto A; Colón-Bolea P; Casar B; Jones M; Agudo-Ibáñez L; Vidal R; Tenbaum SP; Nuciforo P; Valdizán EM; Horvath Z; Orfi L; Pineda-Lucena A; Bony E; Keri G; Rivas G; Pazos A; Gozalbes R; Palmer HG; Hurlstone A; Crespo P
Cancer Cell; 2015 Aug; 28(2):170-82. PubMed ID: 26267534
[TBL] [Abstract][Full Text] [Related]
15. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.
Hyoda T; Tsujioka T; Nakahara T; Suemori S; Okamoto S; Kataoka M; Tohyama K
Cancer Sci; 2015 Mar; 106(3):287-93. PubMed ID: 25580850
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic modulation of k-ras signaling in colorectal cancer.
Krens LL; Baas JM; Gelderblom H; Guchelaar HJ
Drug Discov Today; 2010 Jul; 15(13-14):502-16. PubMed ID: 20594936
[TBL] [Abstract][Full Text] [Related]
17. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
[TBL] [Abstract][Full Text] [Related]
18. Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway.
Waldmann H; Karaguni IM; Carpintero M; Gourzoulidou E; Herrmann C; Brockmann C; Oschkinat H; Müller O
Angew Chem Int Ed Engl; 2004 Jan; 43(4):454-8. PubMed ID: 14735533
[No Abstract] [Full Text] [Related]
19. A genome-wide Ras-effector interaction network.
Kiel C; Foglierini M; Kuemmerer N; Beltrao P; Serrano L
J Mol Biol; 2007 Jul; 370(5):1020-32. PubMed ID: 17544445
[TBL] [Abstract][Full Text] [Related]
20. Targeting RAS signalling pathways in cancer therapy.
Downward J
Nat Rev Cancer; 2003 Jan; 3(1):11-22. PubMed ID: 12509763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
